Allergan Aesthetics is pairing new hallmarks-of-aging science with real skin data from people on weight-loss drugs.
Skin has quietly become one of the more interesting frontiers in longevity science. Not because anyone thinks smoother skin adds years to a life, but because skin is one of the few organs researchers can watch age in real time, poke at, biopsy, and photograph before and after an intervention. That’s part of why Allergan Aesthetics, the AbbVie-owned company behind SkinMedica, brought its R&D team to the 2026 Science of Skin Summit in Austin, Texas, 17–20 September [1].
The company had two things to talk about, and they’re more connected than they first appear.
A framework for a messy new category
The first is a scientific framework for a technology that’s currently more hype than standard: exosomes. These are tiny particles cells use to communicate, and skincare brands have started packing them into serums on the promise that they can signal skin cells to behave more youthfully. The problem, according to Allergan Aesthetics, is that nobody agrees on what “exosome skincare” actually needs to prove before it’s trustworthy.
“An ingredient list tells only part of the story,” said Dr Prithwiraj Maitra, vice president of skincare research and development at Allergan Aesthetics. “Scientific rigor also requires understanding whether biological activity remains intact and stable within the final bottled formulation.”
To address that, the company is introducing something it calls the FACTS Principles, a checklist covering formulation and stability, analysis, clinical studies, cellular origin and safety [2]. It’s not a regulatory standard, and Allergan Aesthetics isn’t claiming it will become one. But it’s a signal that the industry wants a shared vocabulary before exosome skincare gets ahead of the evidence, a pattern that’s played out before in other corners of longevity-adjacent wellness.
At the summit, that conversation runs alongside sessions with names like A Framework for Targeting the Hallmarks of Aging and Separating Signal from Noise in Longevity Science, led by Dr Stephanie Manson Brown, the company’s head of clinical development. Those hallmarks – the biological mechanisms researchers increasingly use to define aging itself – are the same ones showing up in geroscience research far beyond skincare. Applying them to skin, arguably the most visible and most-studied organ system, gives the field a useful testing ground.
“The future of skincare will be shaped not only by how skin looks, but by how well we understand and support the biological systems that help it function over time,” Manson Brown said.
What happens to skin on weight-loss drugs
The second piece of news is more concrete. Allergan Aesthetics ran two small clinical studies looking at what happens to skin in people taking GLP-1 medications for weight loss, and the results speak to something dermatologists have been noticing anecdotally for a couple of years now: rapid weight loss can leave skin looking loose, crepey, or aged before its time.
In a 12-week study, nine participants used a skincare regimen (a growth factor serum, neck cream, and firming body lotion). In a six-week study, 11 participants combined that regimen with DiamondGlow, a dermabrasion treatment [1]. Both studies found statistically significant, investigator-assessed improvements in things like dryness, tone evenness, crepiness and texture, with some changes showing up as early as week two.
The self-reported numbers are the ones likely to grab attention outside the clinical world. Participants in the 12-week study said their facial skin looked around 10 years younger after four weeks of twice-daily serum use. In the six-week study, participants reported skin looking about 7.5 years younger after three DiamondGlow treatments plus the topical regimen. Those are perception measures, not biological age tests, and the study groups are small, but they point to a real and growing clinical question.
“As medical weight loss therapies continue to transform patient health, there is growing interest in understanding associated changes in skin quality, including firmness, laxity and crepiness,” said Elizabeth Makino, co-author of both studies and director of clinical development and global scientific affairs at Allergan Aesthetics. She was careful to frame this as early evidence: “Additional research in larger populations will help further characterize these findings.”
Why it lands on the longevity radar
Put the two announcements together and a pattern emerges. As more people extend their healthy years through metabolic drugs, better diagnostics and behavioral changes, the visible signs of aging don’t always keep pace with the biological ones. Skin is becoming a proxy battleground for that mismatch, and companies like Allergan Aesthetics are trying to build the evidence base before the marketing claims outrun it.
[1] https://news.allerganaesthetics.com/News/detail?releasePath=/2026/9/pr-id-123721
[2] https://news.allerganaesthetics.com/News/detail?releasePath=/2026/9/pr-id-123719
